Matthew B. Klein - Net Worth and Insider Trading

Matthew B. Klein Net Worth

The estimated net worth of Matthew B. Klein is at least $9 Million dollars as of 2024-10-10. Matthew B. Klein is the CHIEF EXECUTIVE OFFICER of PTC Therapeutics Inc and owns about 225,807 shares of PTC Therapeutics Inc (PTCT) stock worth over $9 Million. Details can be seen in Matthew B. Klein's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Matthew B. Klein has not made any transactions after 2024-04-19 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Matthew B. Klein

To

Matthew B. Klein Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Matthew B. Klein owns 2 companies in total, including PTC Therapeutics Inc (PTCT) , and ClearPoint Neuro Inc (CLPT) .

Click here to see the complete history of Matthew B. Klein’s form 4 insider trades.

Insider Ownership Summary of Matthew B. Klein

Ticker Comapny Transaction Date Type of Owner
PTCT PTC Therapeutics Inc 2024-04-19 Chief Development Officer
CLPT ClearPoint Neuro Inc 2020-04-16 director

Matthew B. Klein Latest Holdings Summary

Matthew B. Klein currently owns a total of 1 stock. Matthew B. Klein owns 225,807 shares of PTC Therapeutics Inc (PTCT) as of April 19, 2024, with a value of $9 Million.

Latest Holdings of Matthew B. Klein

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PTCT PTC Therapeutics Inc 2024-04-19 225,807 39.05 8,816,634

Holding Weightings of Matthew B. Klein


Matthew B. Klein Form 4 Trading Tracker

According to the SEC Form 4 filings, Matthew B. Klein has made a total of 12 transactions in PTC Therapeutics Inc (PTCT) over the past 5 years, including 0 buys and 12 sells. The most-recent trade in PTC Therapeutics Inc is the sale of 3,361 shares on April 19, 2024, which brought Matthew B. Klein around $83,655.

Insider Trading History of Matthew B. Klein

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Matthew B. Klein Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Matthew B. Klein Ownership Network

Ownership Network List of Matthew B. Klein

No Data

Ownership Network Relation of Matthew B. Klein

Insider Network Chart

Matthew B. Klein Owned Company Details

What does PTC Therapeutics Inc do?

Who are the key executives at PTC Therapeutics Inc?

Matthew B. Klein is the Chief Development Officer of PTC Therapeutics Inc. Other key executives at PTC Therapeutics Inc include CHIEF FINANCIAL OFFICER Pierre Gravier , Chief Medical Officer Lee Scott Golden , and Chief Business Officer Eric Pauwels .

PTC Therapeutics Inc (PTCT) Insider Trades Summary

Over the past 18 months, Matthew B. Klein made 5 insider transaction in PTC Therapeutics Inc (PTCT) with a net sale of 23,666. Other recent insider transactions involving PTC Therapeutics Inc (PTCT) include a net sale of 22,771 shares made by Eric Pauwels , a net sale of 66,112 shares made by Mark Elliott Boulding , and a net sale of 7,851 shares made by Christine Marie Utter .

In summary, during the past 3 months, insiders sold 2,269 shares of PTC Therapeutics Inc (PTCT) in total and bought 0 shares, with a net sale of 2,269 shares. During the past 18 months, 221,617 shares of PTC Therapeutics Inc (PTCT) were sold and 7,700 shares were bought by its insiders, resulting in a net sale of 213,917 shares.

PTC Therapeutics Inc (PTCT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

PTC Therapeutics Inc Insider Transactions

No Available Data

Matthew B. Klein Mailing Address

Above is the net worth, insider trading, and ownership report for Matthew B. Klein. You might contact Matthew B. Klein via mailing address: C/o Ptc Therapeutics, Inc., 100 Corporate Court, South Plainfield Nj 07080.

Discussions on Matthew B. Klein

No discussions yet.